GLP-1RA及SGLT-2i是ADA和中华医学会糖尿病学分会推荐的新型降糖药物,具有低血糖风险小、兼具心血管保护及降低体重等代谢获益的特点。高尿酸血症是2型糖尿病的独立危险因素,在临床实践中,人们一直在关注预防SUA的升高。据估计,患者SUA...GLP-1RA及SGLT-2i是ADA和中华医学会糖尿病学分会推荐的新型降糖药物,具有低血糖风险小、兼具心血管保护及降低体重等代谢获益的特点。高尿酸血症是2型糖尿病的独立危险因素,在临床实践中,人们一直在关注预防SUA的升高。据估计,患者SUA每升高1 mg/dl,发生T2DM的风险就会增加17%。国内外学者研究结果提示SGLT-2i能兼顾降糖的同时降低SUA水平;最近国外研究显示GLP-1RA还可以降低SUA水平,但仍存在矛盾。国内学者对此研究报告甚少。还需要更多的研究填补此领域的空白,为更好地预防2型糖尿的发生及发展作出贡献。GLP-1RA and SGLT-2i are new hypoglycemic drugs recommended by ADA and Diabetes Branch of Chinese Medical Association, which have the characteristics of low risk of hypoglycemia, metabolic benefits such as cardiovascular protection and weight reduction. Hyperuricemia is an independent risk factor for type 2 diabetes, and much attention has been paid to the prevention of elevated SUA in clinical practice. It is estimated that every 1 mg/dl elevation of patient SUA causes a 17% increase in the risk of developing T2DM. The results of domestic and foreign scholars suggest that SGLT-2i can reduce SUA level while lowering glucose;recent foreign studies show that GLP-1RA can also reduce SUA level, but there are still contradictions. Domestic scholars have few reports on this. More studies are needed to fill the gap in this field to contribute to better prevention of the occurrence and development of type 2 diabetes mellitus.展开更多
An integrated sensing and communication(ISAC)scheme for a millimeter wave(mmWave)multiple-input multiple-output orthogonal frequency division multiplexing(MIMO-OFDM)Vehicle-to-Infrastructure(V2I)system is presented,in...An integrated sensing and communication(ISAC)scheme for a millimeter wave(mmWave)multiple-input multiple-output orthogonal frequency division multiplexing(MIMO-OFDM)Vehicle-to-Infrastructure(V2I)system is presented,in which both the access point(AP)and the vehicle are equipped with large antenna arrays and employ hybrid analog and digital beamforming structures to compensate the path loss,meanwhile compromise between hardware complexity and system performance.Based on the sparse scattering nature of the mmWave channel,the received signal at the AP is organized to a four-order tensor by the introduced novel frame structure.A CANDECOMP/PARAFAC(CP)decomposition-based method is proposed for time-varying channel parameter extraction,including angles of departure/arrival(AoDs/AoAs),Doppler shift,time delay and path gain.Then leveraging the estimates of channel parameters,a nonlinear weighted least-square problem is proposed to recover the location accurately,heading and velocity of vehicles.Simulation results show that the proposed methods are effective and efficient in time-varying channel estimation and vehicle sensing in mmWave MIMOOFDM V2I systems.展开更多
In recent years, the progress of NAFLD has become an important health problem, and the prevention or delay of progress in NAFLD is a major key point. Whether or not to combine T2MD, people are interested in the mechan...In recent years, the progress of NAFLD has become an important health problem, and the prevention or delay of progress in NAFLD is a major key point. Whether or not to combine T2MD, people are interested in the mechanisms and efficacy of SGLT2i for NAFLD. In this review, we summarized the current clinical research on SGLT2i for the combination of T2MD’s NAFLD patients, and the latest evidence of external or animal experiments. These evidences will help us to more accurately understand the protective effects of SGLT2i in NAFLD. Lifestyle changes are still essential to prevent and treat NAFLD, and for all kinds of drugs that treat NAFLD in clinical trials, SGLT2i may be one of the promising treatments.展开更多
目的:观察在慢性心力衰竭的临床治疗中,芪苈强心胶囊联合含钠-葡萄糖共转运蛋白2抑制剂(sodium glucose cotransporter 2 inhibitors,SGLT2is)新四联治疗的应用效果。方法:按照随机信封法对2021年9月—2023年6月克孜勒苏柯尔克孜自治州...目的:观察在慢性心力衰竭的临床治疗中,芪苈强心胶囊联合含钠-葡萄糖共转运蛋白2抑制剂(sodium glucose cotransporter 2 inhibitors,SGLT2is)新四联治疗的应用效果。方法:按照随机信封法对2021年9月—2023年6月克孜勒苏柯尔克孜自治州人民医院收治的80例慢性心力衰竭患者进行分组。对照组(40例)采用含SGLT2is新四联治疗,研究组(40例)联用芪苈强心胶囊,比较两组应用效果。结果:研究组治疗后6个月治疗总有效率、平均动脉压、左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张早晚期充盈速度比(ventricular early to late diastolic filling velocity ratio,E/A),及治疗后1个月一氧化氮(nitric oxide,NO)水平高于对照组,且治疗后6个月左心室收缩末期容积指数(left ventricular end systolic volume index,LVESVI)、左心室舒张末期容积指数(left ventricular end diastolic volume index,LVEDVI),治疗后1个月的静息心率和氨基末端脑钠肽前体(N terminal pro B type natriuretic peptide,NT-proBNP)、内皮素-1(endothelin-1,ET-1)水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:芪苈强心胶囊联合含SGLT2is新四联治疗能够显著缓解慢性心力衰竭患者血管内皮功能障碍,恢复静脉系统血液循环,提高心功能,治疗安全性和实用性较高。展开更多
文摘GLP-1RA及SGLT-2i是ADA和中华医学会糖尿病学分会推荐的新型降糖药物,具有低血糖风险小、兼具心血管保护及降低体重等代谢获益的特点。高尿酸血症是2型糖尿病的独立危险因素,在临床实践中,人们一直在关注预防SUA的升高。据估计,患者SUA每升高1 mg/dl,发生T2DM的风险就会增加17%。国内外学者研究结果提示SGLT-2i能兼顾降糖的同时降低SUA水平;最近国外研究显示GLP-1RA还可以降低SUA水平,但仍存在矛盾。国内学者对此研究报告甚少。还需要更多的研究填补此领域的空白,为更好地预防2型糖尿的发生及发展作出贡献。GLP-1RA and SGLT-2i are new hypoglycemic drugs recommended by ADA and Diabetes Branch of Chinese Medical Association, which have the characteristics of low risk of hypoglycemia, metabolic benefits such as cardiovascular protection and weight reduction. Hyperuricemia is an independent risk factor for type 2 diabetes, and much attention has been paid to the prevention of elevated SUA in clinical practice. It is estimated that every 1 mg/dl elevation of patient SUA causes a 17% increase in the risk of developing T2DM. The results of domestic and foreign scholars suggest that SGLT-2i can reduce SUA level while lowering glucose;recent foreign studies show that GLP-1RA can also reduce SUA level, but there are still contradictions. Domestic scholars have few reports on this. More studies are needed to fill the gap in this field to contribute to better prevention of the occurrence and development of type 2 diabetes mellitus.
文摘An integrated sensing and communication(ISAC)scheme for a millimeter wave(mmWave)multiple-input multiple-output orthogonal frequency division multiplexing(MIMO-OFDM)Vehicle-to-Infrastructure(V2I)system is presented,in which both the access point(AP)and the vehicle are equipped with large antenna arrays and employ hybrid analog and digital beamforming structures to compensate the path loss,meanwhile compromise between hardware complexity and system performance.Based on the sparse scattering nature of the mmWave channel,the received signal at the AP is organized to a four-order tensor by the introduced novel frame structure.A CANDECOMP/PARAFAC(CP)decomposition-based method is proposed for time-varying channel parameter extraction,including angles of departure/arrival(AoDs/AoAs),Doppler shift,time delay and path gain.Then leveraging the estimates of channel parameters,a nonlinear weighted least-square problem is proposed to recover the location accurately,heading and velocity of vehicles.Simulation results show that the proposed methods are effective and efficient in time-varying channel estimation and vehicle sensing in mmWave MIMOOFDM V2I systems.
文摘In recent years, the progress of NAFLD has become an important health problem, and the prevention or delay of progress in NAFLD is a major key point. Whether or not to combine T2MD, people are interested in the mechanisms and efficacy of SGLT2i for NAFLD. In this review, we summarized the current clinical research on SGLT2i for the combination of T2MD’s NAFLD patients, and the latest evidence of external or animal experiments. These evidences will help us to more accurately understand the protective effects of SGLT2i in NAFLD. Lifestyle changes are still essential to prevent and treat NAFLD, and for all kinds of drugs that treat NAFLD in clinical trials, SGLT2i may be one of the promising treatments.
文摘目的:观察在慢性心力衰竭的临床治疗中,芪苈强心胶囊联合含钠-葡萄糖共转运蛋白2抑制剂(sodium glucose cotransporter 2 inhibitors,SGLT2is)新四联治疗的应用效果。方法:按照随机信封法对2021年9月—2023年6月克孜勒苏柯尔克孜自治州人民医院收治的80例慢性心力衰竭患者进行分组。对照组(40例)采用含SGLT2is新四联治疗,研究组(40例)联用芪苈强心胶囊,比较两组应用效果。结果:研究组治疗后6个月治疗总有效率、平均动脉压、左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张早晚期充盈速度比(ventricular early to late diastolic filling velocity ratio,E/A),及治疗后1个月一氧化氮(nitric oxide,NO)水平高于对照组,且治疗后6个月左心室收缩末期容积指数(left ventricular end systolic volume index,LVESVI)、左心室舒张末期容积指数(left ventricular end diastolic volume index,LVEDVI),治疗后1个月的静息心率和氨基末端脑钠肽前体(N terminal pro B type natriuretic peptide,NT-proBNP)、内皮素-1(endothelin-1,ET-1)水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:芪苈强心胶囊联合含SGLT2is新四联治疗能够显著缓解慢性心力衰竭患者血管内皮功能障碍,恢复静脉系统血液循环,提高心功能,治疗安全性和实用性较高。
